A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pioglitazone and Metformin (Actoplus Met)

First FDA approval2005-08-29
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.282/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.332
Across all dosage forms in distribution.
Highest NADAC
$0.383
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Pioglitazone and Metformin used for?

Pioglitazone and Metformin is a this drug class medication tracked in Medicare Part D.

Is there a generic for Pioglitazone and Metformin?

Yes. 8 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Pioglitazone and Metformin?

Across 329 Part D plans, Pioglitazone and Metformin averages $0.332/unit (NADAC). Lowest available: $0.282/unit. Highest in distribution: $0.383/unit.

Is Pioglitazone and Metformin on the FDA shortage list?

No. Pioglitazone and Metformin is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (9 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.